METTL13 and cancer: Interestingly, both METTL13 and two of the other eEF1A-specific MTases, eEF1A-KMT1 and eEF1A-KMT3, are found in the ‘Selective’ category, and, conceivably, highly specific inhibitors directed towards these MTases may find applications as cancer drugs towards certain cancers, and with less side effects than drugs that target essential MTases.